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ABSTRACT
Prostatitis is an inflammatory disease, when the prostate is vulnerable to infectious stimuli like urinary pathogens, are changes in the lifestyle leads 
to inflammation in the prostate gland. It is a pathological state where the swelling of prostate occur to most of the men and mainly elderly. Recently, 
prostatitis is a dangerous threat for men almost 50% total men population. The review comprises complete information regarding prostatitis and 
its related complications. The compilation of the data is about the disease from classification of prostatitis, causative agents, symptoms, treatment, 
mitigation, natural and alternative therapy to improve the quality of life. Awareness of this disease is not known to the majority of the population 
when it is left untreated identification and treatment at the right time help in increase in recovering from the pathological condition of the victim to 
overcome.
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INTRODUCTION
The prostate gland is an essential male reproductive organ which 
is a muscular gland present beneath the bladder the and surrounds 
urethra about the size of a small apricot its pivot function is to secrete 
prostate fluid and also help propel seminal fluid into the urethra during 
ejaculation. The action of the prostate gland is similar to the epiglottis, 
that is, the urethra is the only path for excreting the urine from the 
bladder, and also the semen fluids are discharged. Vas deferens passed 
through the prostate gland and connected to the urethra, during the 
ejaculation millions of sperm moves from testes through vas deferens 
into the region of the prostate gland. At this point, prostate gland 
regulates the movement of sperm into the urethra by contraction 
causing a closing off, opening bladder, and urethra [1].
The prostate fluid makes up the about one-third of the total volume of 
semen, enzymes zinc, and citric acid, the liquid is slightly acid in nature 
and the fluid secreted by the seminal vesicle is alkaline. This alkalinity 
helps to protect sperm, prolong their life in an acidic environment of 
the vagina.
Prostate-specific antigen (PSA) is an enzyme which is one of the major 
components of the prostatic fluid that regulate the sperm motility, 
liquefying semen during ejaculation and thickened after ejaculation. 
PSA aids the biochemical change.
Prostatitis is state of inflammation of prostate gland which causes which 
cause painful and difficult in urination and obstruct the vas deferens 
which connect urethra. Almost half of the men in their 60 years suffer 
from the growth of the prostate called benign prostatic hyperplasia 
(BPH), according to the Ohio State University Medical Centre. By the 
age of 70–80, they are prone to nearly 90% chance of developing BPH. 
Symptoms include urination, dribbling, and a stuttered or weak stream.
EPIDEMIOLOGY
The prevalence of prostatitis can occur from young adult men to elders; 
there are various reasons for the occurrence of prostate inflammation 
is mainly due to urinary tract infection especially bacteria is one of 
the significant factors affecting. Acute bacterial prostatitis (ABP) is 
acquired by 50% of men commonly. CP/CPPS incidence lies between 
2 and 16% worldwide in men below 50 years old [2]. Symptoms can 
found on average 87 months prior diagnosis. Its undesirable impact on 
quality of life (QOL) compares to other illnesses. The relative prevalence 
of other entities among men with prostatitis is 10 to 65% nonbacterial 
prostatitis and 30 to 80% prostatodynia.
CATEGORIES OF PROSTATITIS
The National Institute of Health (NIH) consensus has categorized 
prostatitis into four distinct types are (a) acute prostatitis, (b) 
chronic bacterial, (c) inflammatory/non-inflammatory chronic, and 
(d) asymptomatic inflammatory [1].
ABP
Acute prostatitis is caused by bacteria that infect the prostate gland and 
cause inflammation and pain it lasts for a short time, i.e. for 3 weeks 
to <3 months which are called acute prostatitis. When it extends its 
spam beyond the stipulation of 3 months, called as chronic bacterial 
prostatitis. The causative agents for inflammation and infection of the 
prostate are Escherichia coli in mostly and also Chlamydia trachomatis, 
Enterococcus spp., Klebsiella pneumonia, Neisseria gonorrhea, Proteus 
mirabilis, Pseudomonas aeruginosa, and Staphylococcus aureus [3,4]. 
These bacteria invade the prostate gland and cause infection by 
consuming contaminated animal products (example chicken), discharge 
of urination in an unsanitary environment, and contract through sexual 
activity from a partner who has a bacterial infection. Men suffering from 
chronic who intermittently perform self-catheterization, indwelling 
catheters, immunosuppression, and diabetes mellitus, are at higher risk 
of acquiring ABP due to their increased risk of bacterial colonization of 
the urethra.
The clinical exhibition of ABP may be highly variable with symptoms 
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ABP has to be deliberate in the diagnosis of the male with urinary tract 
infection	symptom.	During	the	physical	examination,	tender	palpation	of	
the prostate gland generally acknowledges a pathognomonic finding of 
an impeccably tender, boggy prostate gland, care should be taken to avoid 
vigorous prostate massage as this may precipitate bacteremia and sepsis.
ABP diagnosed clinically, in spite of both urine culture and urine Gram 
stain and are recommended to find causative organisms and determine 
treatment. While C-reactive protein and blood cultures are essential, 
a PSA test not indicated. PSA elevations are common in the setting of 
infection and may take up to 1-month post-infection to resolve. Imaging 
only shows imaging is performed when a prostatic abscess suspect in 
a patient with ABP who is failing to improve with treatment, in order 
to differentiate between and acute bacterial prostatitis and prostate 
cancer.
CHRONIC BACTERIAL PROSTATITIS
Chronic prostatitis also caused by the above bacteria and also the by 
Trichomonas vaginalis, Ureaplasma urealyticum, Mycoplasma hominids, 
and Serratia marcescens these do not grow in the standard condition, and 
it is hard to identify and treat these bacteria are quite rare in affecting 
nearly 80% cases are E. coli and C. trachomatis, Enterococcus spp., 
K. pneumonia, N. gonorrhoea, and P. mirabilis. A study has shown that 8% of 
chronic prostatitis had positive specific polymerase chain reaction assay. 
Chronic	prostatitis	patient	has	a	distinct	variety	of	bacterial	DNA	encoding	
sequence despite extensive negative microbiological investigations [5].
Chronic pelvic pain syndrome or chronic prostatitis (CPPS/CP) and 
interstitial cystitis/bladder pain syndrome defined by the absence 
of identifiable bacterial infection as a cause for the chronic pain and 
urinary symptoms. It classified into two types they are inflammation 
subtype and non-inflammation subtype according to the NIH. The 
etiology of this type is poorly understood both inflammatory and 
infectious mechanism have postulate [6-8]. Psychological stress may 
be a major contributor to symptom severity [9]. Some data prevail of 
a correlation between fibromyalgia, chronic fatigue syndrome, and 
irritable bowel syndrome with CP/CPPS, although certain association 
exists between the number of inflammatory markers detected within 
the prostate gland and the degree of symptoms [10,11].
Symptoms of CP/CPPS are a weak urinary stream, dysuria, 
urinary frequency, urinary urgency, pain in the lower abdomen, 
perineum, testicles or penis; hematospermia or difficulty achieving 
an erection [12,13]. According to diagnosis in the patient to have pelvic 
pain or urinary symptoms for more than three of the previous 6 months 
with no evidence of ABP or urinary tract infection in that time [14]. 
CPPS/CP accounts for 90% of prostatitis cases in outpatient clinics and 
characterized by chronic pelvic pain symptoms lasting at least 3 months 
during the past 6 months, in the absence of a urinary tract bacterial 
infection but the presence of urinary symptoms and sexual dysfunction.
ASYMPTOMATIC INFLAMMATORY PROSTATITIS
Asymptomatic inflammatory prostatitis refers on to the word 
asymptomatic.	 During	 infertility	 or	 prostate	 cancer	 evaluation,	
this asymptomatic inflammatory prostatitis diagnosed 
incidentally. [15] According to the clinical indication of category IV 
prostatitis i.e., asymptomatic inflammatory prostatitis is unaware by 
the patients and is often left untreated; because there is an inflammation 
of the prostate but there is no symptoms of genital urinary tract 
infection has no symptoms of pelvic pain. There are two typical signs 
of asymptomatic inflammatory prostatitis, the presence of white blood 
cells or pus cells in the urine and elevated PSA level; this condition 
commonly observed in BPH.
CONSEQUENCES OF PROSTATITIS
Chronic inflammation of prostatitis plays a significant role in 
pathogenesis and progression of BPH and prostate cancer according to 
preclinical trials [16].
BPH
Approximately 40–70% of patients suffering in BPH-related lower 
urinary tract symptoms (LUTS) found with chronic inflammation 
pathologic evaluation [16]. Recent studies exploring inflammasomes 
in prostate showed prostate expression of nucleotide-binding domain 
leucine-rich repeat protein 1 (NLRP1), NLRP3, and absent-in-melanoma 
2 [17-19], though BPH and prostatitis are distinct entities, there are 
significant clinical overlap and critical inflammatory component in 
both [19]. Inflammation has also viewed as a relevant factor in the 
pathogenesis of BPH. Studies showed infiltrating lymphocytes in the 
development and progression of prostate adenoma as an effect of a 
self-maintaining remodeling process [21]. Histological analysis of 
prostatic tissue remains the only available method to diagnose chronic 
inflammation. However, chronic inflammation of prostate may be 
associated with prostatic calcifications, prostate volume, LUTS severity, 
storage, and prostatitis-like symptoms, inadequate response to medical 
therapies and urinary biomarker [22]. Chronic inflammation could be 
a predictor of insufficient response to BPH medical treatment. Studies 
had shown that men with BPH related LUTS and chronic prostate 
inflammation might have increased risk of symptom progression and 
acute urinary retention during follow-up.
PROSTATE CANCER
Inflammation had been found in about 20% of all human malignancies 
in a tissue microenvironment. Chronic inflammation is an inducer for 
most prostate malignancy. Chronic inflammation which aids to prostate 
cancer tissue when medically treated by surgery has given an adverse 
outcome. Prostate epithelium may damage with various environmental 
factor they are infectious agents, dietary carcinogens, and hormonal 
changes which trigger procarcinogenic inflammatory process and 
leads to cell transformation. Proliferative inflammatory atrophy, mainly 
in the peripheral prostate zone, refers to chronic inflammation and 
carcinogenesis cooccurring. This a probable precursor of prostatic 
intraepithelial neoplasia and prostate cancer [23]. Transcription 
factor	nuclear	 factor-kappa	B	(NF-kB)	activation	has	been	recognized	
as the significant effecter of pro-inflammatory processes as well as 




through positive feedback with inflammatory cytokines. However, some 
studies suggest inflammation may relate with lower. Prostate cancer 
risk [26,27] and some showed that inflammatory genes expressed 
differently among races in prostate cancer [28,29].
CAUSE OF PROSTATITIS
Various modes of stimuli and components occur the cause of prostatitis. 
And also, due to unhealthy habitat and diet are majorly proposed to 
the vulnerable causative agents of the various categories of prostate 
inflammation or prostatitis [30].
INFECTIOUS STIMULI
Uropathogens mainly Gram-negative bacilli are most often causes 
bacterial prostatitis, and Gram-positive identified as the causative 
organism of chronic prostatitis C. trachomatis and trichomonasvaginalis 
are common pathogens cause chronic prostate inflammation sexually 
transmitted diseases. In general, these categories of prostatitis caused 
due to unhygienic urination, and unhealthy sexual habits play a key role 
in infectious prostatitis.
NON INFECTIOUS STIMULI
Prostatic inflammation is of multiple etiologies. Urine refluxed 
freely into the prostatic ducts [31] can provide a route for bacterial 
colonization [32,33]. Other potential factors include dietary 
components, changes in serum testosterone and estrogen levels 
autoimmunity, and reflux of harmful chemicals in the urine. Besides, 
3
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prostate inflammation can trigger metabolic alterations including 
metabolic syndrome and dyslipidemia [34-36]. Recent studies showed 
that smoking and a high-fat diet might relate with prostate inflammation. 
In	a	univariable	analysis	in	Reduction	by	Dutasteride	of	Prostate	Cancer	
Events study, smoking associated with chronic prostate inflammation. 
Current smokers were prone to have acute inflammation and chronic 
inflammation in the baseline biopsy [37]. On the other hand, a high-
fat diet may induce oxidative stress and inflammation in the prostate 
gland by driving the nicotinamide adenine dinucleotide phosphate 
oxidase system and generating reactive oxygen species (ROS) [38]. 
A high-fat diet also causes a significant increase in proinflammatory 
cytokines through activation of Signal Transducer and Activator of 
Transcription-3	and	NF-kB	pathway.	Both	these	pathways	 involved	 in	
proliferation, survival, angiogenesis, invasion, and inflammation in the 
prostate.
SEROUS COMPONENT OF PROSTATE
Besides, the cytokines directly made by cellular counterparts of 
prostate inflammation, the resistance has special sorts of activation in 
prostate inflammation. There are two sorts of patterns of the stimuli 
which will activate the innate system; one is pathogen-associated 
molecular patterns (PAMPs), and also an alternative is danger-
associated	molecular	 patterns	 (DAMPs),	 that	 is,	 especially	molecules	
derived from broken or dying cells. These patterns are recognized by 
pattern recognition receptors (PRRs), which can found in specialized 
epithelia, immune cells, and alternative tissues. PRRs divided into 
five families, together with toll-like receptors (TLRs), C-type lectins, 
retinoic acid-inducible gene-I-like receptors, and HIN-200, and NLRs. 
The means some members of the NLR and HIN-200 families answer 
DAMPs	 or	 PAMPs	 are	 by	 forming	 supramolecular	 structures	 called	
inflammasomes. They will typically mix adapter molecules similar 
to apoptosis-associated speck-like supermolecule (ASC). These 
structures activate the aminoalkanoic acid enzyme caspase-1, that 
cleaves pro-interleukin 1 beta (IL-1b) to IL-1b and pro-IL-18 to IL-18. 
These mature cytokines are pro-inflammatory, and so they trigger a 
typical inflammatory response. The inflammasome is called once the 
PRR that organizes it. Parenthetically, NLRP3 is associate in nursing 
inflammasome	organized	by	NACHT,	LRR,	and	PYD	domains-containing	
supermolecule three, that play a crucial role in many urologic pathology. 
Typically the chronic inflammation starts with inflammasome, which is 
initiated by a canonical and noncanonical pathway [39-42].
The first step, priming is related to ligand binding to a non NLR 
receptor. It can increase the expression of inflammasome components. 
For	instance	is	LPS	binding	to	Toll-like	receptor	4	(TLR4),	that	increase	
the expression of ASC, NLRP3, Caspase-1, and pro-IL-Ib [43].
Priming additionally promotes preexistent NLRP3 by deubiquitination, 
thus refer it for activation. IL-18 usually constitutively expressed.
The second step, activation is triggered by certain stimuli and result 
in cellular changes. Stimuli events embrace the presence of ROS, 
extracellular adenosine triphosphate binding with the purinergic 
receptor, or insoluble crystals damaging the semipermeable membrane. 
Cellular changes embrace production of ROS, potassium efflux from 
the cell, translocation of NLRP3 to the mitochondria; this leads to the 
mitochondrial	 degradation	 with	 unleashing	 of	 DNA	 and	 cardiolipin,	
and activation, which triggers nucleation of ASC proteins. They will 
interact with procaspase-1, and promote autoproteolytic maturation 
of caspase-1. Activated caspsase-1 is then free from the complex and 
cleaves pro-IL-Ib and pro-IL-I8 to their mature forms. Active caspase-1 
may	 also	 cleave	 gasdermin	 D	 which	 can	 begin	 a	 lytic	 necrobiosis	
process called proptosis [44-46]. Inflammation exacerbation increased 
in proptosis, as a result of it ends in the discharge of the mature Il-1b, 
IL-18,	and	DAMPs	such	as	uric	acid	[47],	ATP,	and	high	motile	group	box	
1. High motile group box 1(HMGB1), which then activate inflammasome 
in neighbour cells. The free ASC-containing increases the uptake by 
macrophages, which start inflammasome activation within, or mature 
procytokinines in extracellular in extracellular space. N terminus 
osgasdermin	D	itself	can	also	promote	NLRP3	dependent	activation	of	
caspase-1 [48].
The non-canonical pathway is the alternative way of activating NLRP3 
inflammasome complex. There involve caspase-4 and 5 in humans and 
caspase-11 in rodents [49-51]. These caspases are activated by direct-
binding to intracellular bacteria or LPS. Once activated, caspase-11 
can trigger the formation of the macromolecular inflammasome and 
activates downstream events. However, caspase-11 can also cleave 
gasdermin directly and induce pyroptosis even without inflammasome 
formation.
Seminal plasma IL-8 (SIL-8) appears to be the most reliable and 
predictive	 marker	 of	 prostatitis	 [52].	 Furthermore,	 the	 evidence	
is emerging on SIL-8 involvement in inflammation not only of the 
prostate but also of other male genital tract organs, in particular, 
seminal vesicles and epididymis, but not testis. SIL-8 is strongly related 
to leukocytospermia, and a tight inverse correlation with ejaculate 
volume has demonstrated, which may correlate with ejaculatory duct 
and seminal vesicle abnormalities.
CELLULAR COMPONENT OF PROSTATE INFLAMMATION
In the initial stage of ABP, the infection of micro-organism promotes 
neutrophils and macrophages continued by lymphocytic infiltration 
in the advanced stages [53]. Later the acute phase, the majority of 
infiltrative leukocytes in the inflamed prostate are chronically activate T 
lymphocytes and macrophages [54,55]. Mouse models of inflammation 
showed very similar infiltrative components as inflamed human 
prostates [56]. Th1 cells control the immune response to intracellular 
pathogens through interferon and IL-2. Type 1 T helper cells produce 
IL-4, IL-13, and IL-5 in the hypersensitivity response. Th17 cells appear 
as host defense against extracellular pathogens through IL-17 and IL-
21. Resident epithelial and stromal cells express several TLRs, including 
TLR-4, TLR-5, TLR-7, and TLR-9, and also produce IL-1, IL-6, and IL-
15 during inflammation [57]. Prostatic epithelial cells express Class II 
major histocompatibility complex molecules that participate in organ-
specific inflammation, resulting in the production of IL-6, IL-8, and 
CXCL10,	and	 leukocyte	 recruitment	 [58].	 Stromal	 cells	 express	CD80,	
CD86,	 CD40,	 and	CD134L	 and	 activate	T	 lymphocytes	 directly.	 These	





2. Urine analysis and culture
3. Imaging
I. Transrectal prostatic ultrasound (TRUS) or computed tomography
II. Pelvic ultrasound or bladder scan.
CHRONIC BACTERIAL PROSTATITIS
1. Physical examination
2. Microbiological localization culture of a lower urinary tract
I. 4-Glass test





1. Symptoms scoring questionnaires (according to NIH-Chronic 
Prostatitis Symptoms Index)
2. Cystoscopy
3. Endoscopy (patients with hematuria)
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4. 4-glass test or PPMT
5. Physiological assessment.
The above categories of prostatitis diagnosed according to the patient 
symptoms, duration, and recurrence of the inflammation in the prostate 
gland. However, asymptomatic prostatitis is identified accidentally 
during the infertility evaluation.
TREATMENT
The treatment for the prostatitis is given broadly illustrating the 
medication, by indigenous system of medicines like allopathic, 




Five	 alpha	 reductase	 inhibitors	 such	 as	 finasteride	 and	 dutasteride,	
Alfuzosin,	 Tamsulosin,	 Doxazosin,	 Terazosin	 are	 broadly	 prescribed	
in the prostatitis patients [61]. These drugs are muscle relaxant at 
the bladder neck, facilitates the urine. These work by targeting the 
symptomatic relief of chronic prostatitis during the painful urination. 
Alpha-blocker has several side effects associated like dizziness, 
insomnia and vertigo. Nonselective alpha-blockers such as doxazosin 
and terazosin (Hytrin) must be used with care because they can 
excessively lower blood pressure. Mostly preferred alpha blockers are 
alfuzosin or tamsulosin produces improvement of urinary symptoms 




of decreasing contraction of the bladder. Cause urinary retention may 
cause to the men suffering enlarged prostate [61].
Nonsteroidal anti-inflammatory drug (NSAID)
The	 NSAID	 drugs	 like	 Aspirin,	 ibuprofen,	 and	 naproxen	 sodium	 are	
prescribed,	 to	 reduce	 pain.	 NSAID	 is	 prescribed	 to	 reduce	 pain	 and	
also	to	reduce	the	 inflammation	pain.	Fluoxetine	(20	mg	orally	daily)	
generally prescribed for depression and to improved QOL [62].
Neuromodulators
Amitriptyline, Nortriptyline and pregabalin are new medication for 
the treatment of prostatitis, prescribed for the urinary frequency 
and urgency. Management of refractory CPP was performed by the 
stimulation of neuromodulation/nerve stimulation. Neuromodulation 
spot the S2–S4 nerve roots even though the pelvis is innervated by 
peripheral sympathetic (T12–L2) and somatic (S2–4), as well as 
parasympathetic (S2–4) nerve structures. Therefore, the exact painful 
location is covered by lead placement at the sacral level, but not a 
satisfactory improvement symptomatically is notice in patients [63].
Muscle relaxant
Cyclobenzaprine, Clonazepam extensively used muscle relaxant. 
Diazepam	and	baclofen	can	be	used	in	Category	IIIB	prostatitis	when	
sphincter dyssynergia or pelvic floor/perineal muscle spasm is 
confirmed. The evidence for this is rather old [64], and the role of these 
agents has not re-evaluated subsequently. They act as a calming agent 
to the central nervous system, help with anxiety, and relax the pelvic 
muscles, thereby reducing muscle spasms. Muscle relaxants are helpful 
in easing the pain and pressure that many CPPS patients experience.
Phytotherapy
Phytotherapies (specifically quercetin and the pollen extract, saw 
palmetto cernilton) [65,66] are optional recommendations for the 
first line of chronic bacterial prostatitis and combination multimodal 
therapy.
Acupuncture
Acupuncture as an effective treatment to improve symptoms of 
CP/CPPS. Compared with sham acupuncture, real acupuncture leads to 
significant reductions in the pain, urinary symptoms, and QOL domains 
of the NIH chronic prostatitis symptom index [67].
PHYSICAL THERAPY
Kegel exercises
Tightening and relaxing the muscles that hold urine in the bladder 
and hold the bladder in its proper position also called pelvic muscle 
exercises.
Myofascial release
Myofascial release is a hand on technique that involves pressure into 
the connective tissue to eliminate pain and restore function and motion 
in affected area. Pressing and stretching of the particular region also 
practices like cooling and warming, of the muscles and soft tissues in 
the lower back, pelvic region, and upper legs leads to relief in pain. Also 
known as myofascial trigger point release (Table 2) [68].
HORMONE THERAPY
The principal activity in hormone therapy is blocking hormonal activity 
leads to the inhibition of growth of cancer cells, for example, luteinizing 
hormone producing hormones, which exhibits the mechanism of action 
that	 can	 cause	 gonadotropin	 secretion	 inhibition.	 Following	 an	 early	
stimulation of gonadotropin, testicular steroidogenesis suppression 
occurs due to long-term administration of leuprolide acetate. It results 
in inhibition of the growth of the specific hormone, proves and shows 
that luteinizing hormone-releasing hormone agonists promote tumors 
(such as prostatic tumors). Examples are buserelin, leuprolide, and 
goserelin [75]. Antiandrogens exert its action by inhibiting androgen 
uptake and by inhibiting nuclear binding of androgen to the androgen 
receptors on prostatic cells such as flutamide and nilutamide. Studies 
are still being accomplished to find the ideal therapy for localized 
prostate cancer.
Clinical management
Clinical management of prostatitis is possible by avoiding ignorance of 
pain and its aided symptoms. Early detection of prostatitis is completely 
curable and monitoring the abnormalities after the recovery of the 
prostatitis is necessary. If the prostatitis is left untreated that leads to the 
chronic stage and later it causes enlargement associated hardening of the 
prostate gland that finally ends resulting in prostate cancer. Identification 
of the exact stage of prostate enlargement whether it is prostatitis or 
prostate cancer by a conventional test such as PSA and digital rectal exam 
for application in clinical practice [76]. There is a strong similarity among 
the clinical and molecular assays in identifying initially and robust cancer 
determination because molecular assays are less aggressive and reliable. 
The genetic markers have the ability to providing useful prognostic or 
Table 1: Treatment of acute and chronic bacterial prostatitis [60]
ABP
Mild or moderate disease while anticipating culture
Trimethoprim 300 mg taken orally 14 days [60], or
Cephalexin 500 mg administered orally b.i.d for 14 days, or
Clavulanic acid and amoxicillin 125 mg+500 mg orally b.i.d for 
14 days
Appears unable to resist or septic anticipated oral therapy
Admit to a hospital, offer parenteral treatment with ampicillin and 
gentamycin or ceftriaxone as persevere pyelonephritis treatment
Chronic bacterial prostate inflammation
The first line of treatment
Norfloxacin 400 mg is administered orally every 12 h for 4 weeks, or
Trimethoprim 300 mg orally daily for 4 weeks
If ureaplasma or chlamydia noted
Doxycycline	100	mg	given	orally	every	12	h	for	2–4	weeks
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predictive information into clinically useful diagnostic tests to improve 
clinical decision-making and enhance therapeutic success.
CONCLUSION
The prostatitis is one of the most common diseases that affect men. 
Treatment of this diseases has to perform according to the patient’s sign 
and symptoms and also the duration of the illness has to consider deeply 
to identify the category of the prostate inflammation and to provide 
appropriate treatment. Various diagnostic procedures have to undergo 
for critical analysis of the type of prostatitis. Many types of research are 
emerging for the treatment of chronic prostatitis in multiple fields such 
as Ayurveda, acupuncture, and physical therapy. Clinical trials are under 
process for hormonal therapy for the curative purpose. The researchers 
are targeting on the anti-inflammatory activity on prostatitis from the 
active phytochemical and isolated compound in natural or crude drugs.
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Table 2: Treatment for different categories of prostatitis on crude drugs [69-74]
S. No Plant name Family/part Primary secondary metabolites/
mechanism of action
Activity exhibited
1 Alisma plantago‑aquatica Linnaeus [69] Alismataceae Terpenes and phenolic acid Anti-chronic prostatic 
activity
2 Phoenix dactylifera	DPP	[70] Arecaceae The	expressions	of	IL-6,	IL-8,	TNF-α,	
IGF-1,	and	clusterin	increased,	while	the	
expression	of	TGF-β1	was	decreased	








3 Cernitin pollen [71] Graminaceae Decreased	the	increased	contents	of	
cytokines
Anti-inflammatory 
action, an inhibitory 
effect on the prostatic 
inflammatory cytokine
4 Tamala (Cinnamomumtamala) [72] Lauraceae Tannins, COX-2 inhibition is reported to 
increase apoptotic activity in the prostatic 




5 Serenoarepens (saw palmetto) [73,74] Arecaceae/palmaceae Free	fatty	acids,	phytosterols	 
(beta-sitosterols and other), aliphatic 
alcohol. Inhibition of prolactin and 
growth factor-induced prostatic cell 
proliferation, and stimulation of 
apoptosis. Stylidium repens extract 
inhibits testosterone-stimulated prostate 
enlargement in rats
A mild diuretic, 
a sedative, an 
anti-inflammatory and 
an antiseptic agent
6 Cucurbitapeponis [73,74] Cucurbitaceae Sterols, carotenoids, minerals (Se, Mg) 
and produces competitive binding to 
androgen receptors, decreased binding 





7 Pygeumafricanum [73,74] Rosaceae Phytosterols (beta-sitosterol), triterpenes, 
long-chain fatty acids Its MOA inhibits 
either	androgens	or	5α-reductase,	it	may	
have direct protective effects by restoring 
structural and functional characteristics 
in the aging prostate
Treatment of BPH
8 Urticadioica radix [73,74] Urticaceae Its active phytochemical constituents 
are Lectins, phenol, sterols, lignans MOA 





9 Allium sativum (garlic) [75] Amaryllidaceae The statistically significant decrease 
in bacterial growth and improvement 
in prostatic inflammation as well as a 
synergistic effect with ciprofloxacin
Useful in treating CBP 
with a higher success 
rate




11 Hypoxis rooperi (South African star 
grass) [74]
Hypoxidaceae Beta-sitosterol, other phytosterols, 
its action is a decrease in ATPase, a 
reduction in cell growth
Anti-inflammatory 
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